Is IQVIA (IQV) a risky stock?
As of July 21, 2026, Clavix grades IQVIA (IQV) C for risk, a composite score of 62 out of 100 on an A+ to F scale, which puts IQV in the "average" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind IQV's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how IQV scores on each, as of July 21, 2026.
What's moving IQV's risk right now
Company-specific signals Clavix flags behind IQV's current grade, drawn from recent news and filings as of July 21, 2026.
IQVIA's Dr. Cynthia Verst told a Congressional subcommittee that the U.S. needs a faster path for clinical trials, putting IQVIA in line to benefit from any resulting reforms. Separately, Sumitomo Mitsui Trust added 93,779 shares and SEB Asset Management opened a new 228,726-share position.
Artisan Partners' Q1 2026 investor letter asked whether IQVIA can hold up against AI disruption to its clinical rating and data business. The piece frames AI as an open competitive threat without offering a clear answer.
What a C grade means
On the Clavix A+ to F scale, IQV's composite of 62 falls in the C band (50–64), read as "average." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell IQV or any security. Grades are risk indicators, not predictions of return. Data may be delayed.